KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Work In Process (2016 - 2020)

Historic Work In Process for Emergent BioSolutions (EBS) over the last 11 years, with Q1 2020 value amounting to $114.2 million.

  • Emergent BioSolutions' Work In Process changed N/A to $114.2 million in Q1 2020 from the same period last year, while for Mar 2020 it was $114.2 million, marking a year-over-year change of. This contributed to the annual value of $89.7 million for FY2019, which is 1308.14% down from last year.
  • Emergent BioSolutions' Work In Process amounted to $114.2 million in Q1 2020.
  • In the past 5 years, Emergent BioSolutions' Work In Process ranged from a high of $119.1 million in Q2 2019 and a low of $14.8 million during Q3 2017
  • Moreover, its 5-year median value for Work In Process was $70.7 million (2017), whereas its average is $64.5 million.
  • Its Work In Process has fluctuated over the past 5 years, first plummeted by 3958.87% in 2017, then surged by 33871.82% in 2018.
  • Over the past 5 years, Emergent BioSolutions' Work In Process (Quarter) stood at $19.8 million in 2016, then soared by 286.46% to $76.6 million in 2017, then skyrocketed by 34.73% to $103.2 million in 2018, then decreased by 13.08% to $89.7 million in 2019, then increased by 27.31% to $114.2 million in 2020.
  • Its Work In Process stands at $114.2 million for Q1 2020, versus $89.7 million for Q4 2019 and $106.6 million for Q3 2019.